# Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

> **NCT03551275** · PHASE1 · COMPLETED · sponsor: **Biocad** · enrollment: 24 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BCD-132

## Key facts

- **NCT ID:** NCT03551275
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-22
- **Primary completion:** 2018-10-18
- **Final completion:** 2019-03-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03551275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03551275, "Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03551275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*